Abstract Number: PB2106
Meeting: ISTH 2020 Congress
Theme: Venous Thromboembolism and Cardioembolism » Cancer Associated Thrombosis
Background: Thrombotic risk occurs in all hemato-oncological entities. It´s well known that this patients have an increased risk of venous thromboembolism (VTE), but it has also been recognized that may be an increased risk of arterial thrombosis.
Aims: To characterize the thrombotic events in patients with hematological malignancies in a second level Hematology Service in Mexico City.
Methods: We conducted a cohort of consecutive patients diagnosed with: lymphoma, myeloma, chronic myeloproliferative syndromes (CMPN) and acute leukemia, who presented at least one thrombotic event (arterial or venous) corroborated by image studies from January 1, 2014 to December 31, 2018.
Results: Forty two cases of thrombosis were identified, 50% were women. Mean age 59 years (26-92 years). VTE ocurred in lower limbs in 57% of cases,in thoracic limbs (30.8%). PT in 14%, portal vein thrombosis in 4.7%, renal thrombosis in 2.3% and thrombosis of suprahepatic veins 2.3%.
The most frequent site of arterial events was cerebral (14% of all thrombotic events).
Thrombosis occurred most frequently in patients with Non Hodgkin Lymphoma: DBCL 35%, FL 4.8%, plasmablastic 4.8%, mantle cell 2.4% and peripheral T 2.4%. Followed by CMPN: essential thrombocythemia 21%, myelofibrosis 2.4%, polycythemia vera 4.8%, chronic myeloid leukemia 2.4%, Hodgkin´s lymphoma 9.5%, multiple myeloma 7.1%, acute myeloid leukemia 2.4%.
The treatment of choice for VTE was low molecular weight heparins. Currently 65% of cases continue with treatment: 32.7% of patients receive low molecular weight heparins, 9.5% rivaroxaban, 11.9% acenocoumarin and 14.3% with ASA for arterial thrombosis.
Conclusions: VTE is the most frequent cause of thrombosis in patients with hematologic malignancies. There is no gender predominance. Venous thrombosis was more frequent in patients with lymphoma and arterial in patients with CMPN. Long-term follow-up is required to determine recurrence and long-term mortality.
To cite this abstract in AMA style:
Ledesma de la Cruz C, García-Lee MT, Guzmán-Chores LO, Castellanos-Galán JE, Lugo-García Y, Juárez-Lara J, Majluf-Cruz AS. Thrombosis in Hematologic Malignancies: A Five Year Single-Center Experience in Mexico [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/thrombosis-in-hematologic-malignancies-a-five-year-single-center-experience-in-mexico/. Accessed September 24, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/thrombosis-in-hematologic-malignancies-a-five-year-single-center-experience-in-mexico/